The U.S. Food and Drug Administration on Wednesday approved Mesoblast's cell therapy for treating a type of complication that ...

Calquence is under clinical development by AstraZeneca and currently in Phase II for Graft Versus Host Disease (GVHD).

TRX-103 is under development for the treatment of graft versus host disease (GvHD), Crohn’s disease and unspecified indication. The therapeutic candidate comprises of allogenic Treg-cells which are ...

New imaging technique able to identify early signs of graft-versus-host-disease in transplant patients. Read on!

Graft-versus-host disease (GvHD) is a complication of a bone marrow or stem cell transplant in which cells from a donor attack the tissues of the recipient. GvHD can be classified as being either ...

Let’s cover six scientifically backed methods to address the post-stem cell transplant procedure side effects you may be experiencing.

The researchers found that itacitinib resulted in low CRS grades; 22%, 78%, and 0% of patients had grades 0, 1, and 2 to 5, respectively. (HealthDay News) — For patients with haploidentical ...

The allogeneic bone marrow-derived mesenchymal stromal cell (MSC) therapy Ryoncil (remestemcel-L-rknd) has been approv ...

Acute GvHD, a common and potentially life-threatening complication of allo-HCT, can have symptoms that mimic irritable bowel disease (IBD), including abdominal pain or cramps, nausea, vomiting ...

Mesoblast's FDA approval for remestemcel marks a milestone for MSC therapies, but limited cash reserves pose risks for US ...

INR:6468. gta san 1 century-old miracle drug & 2 billion-dollar products & 4 blockbuster drugs: the future of antithrombotic drugs is still promising Strategies for the d ...